Immunorho (Human Anti-D Immunoglobulin)

The immunoglobulin binds specifically to the D antigen on Rh‑positive red blood cells. By coating these cells, it blocks the maternal immune system from recognizing them as foreign, thereby preventing the formation of anti‑D antibodies that could cause hemolysis in the fetus or newborn.

The dose of Immunorho is determined by the prescribing clinician based on the patient’s Rh status, gestational age, and clinical guidelines. Healthcare professionals calculate the appropriate volume to achieve effective prophylaxis, and the regimen may vary between antenatal and post‑partum administration.

Immunorho is specifically indicated for use in pregnancy to prevent Rh sensitization. While it is administered to pregnant women, safety data for breastfeeding are limited, and the decision to use the product while nursing should be made by a qualified healthcare provider after weighing potential benefits and risks.

To order Immunorho, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, cold‑chain shipping details, and necessary import documentation.

Immunorho contains purified human anti‑D immunoglobulin similar to other licensed anti‑D preparations. Differences may lie in manufacturing origin, concentration, and regulatory approvals. Clinicians typically select a product based on local availability, cost, and specific formulation characteristics such as volume and storage requirements.

Immunorho must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature, it should be returned to controlled refrigeration promptly to maintain potency.

Immunorho is given as an intramuscular injection, usually into the deltoid or gluteal muscle. The administration is performed by a qualified healthcare professional using aseptic technique. The volume injected depends on the prescribed dose and the concentration of the preparation.

The most serious risks include severe allergic reactions such as anaphylaxis, hemolysis, serum sickness, and rare cases of acute renal failure. Patients should be monitored closely after injection for any signs of hypersensitivity, and emergency measures should be available to manage anaphylactic events.

Immunorho should not be given to individuals with a known severe IgA deficiency who have experienced prior reactions to blood products, or to patients with a documented hypersensitivity to human immunoglobulins. It is also contraindicated in patients who have received another anti‑D preparation within a short interval without medical justification.